STBD1 Antibody

What is STBD1 and what cellular functions does it perform?

STBD1 (starch binding domain-containing protein 1) is a glycogen cargo receptor that mediates glycophagy, a selective form of autophagy characterized by glycogen degradation via the lysosomal enzyme acid α-glucosidase (GAA). STBD1 functions by binding glycogen and facilitating its transport into lysosomes for breakdown . This protein is predominantly localized to the endoplasmic reticulum membrane and plays a crucial role in glycogen metabolism . Recent research has demonstrated that STBD1 is upregulated during endoplasmic reticulum stress conditions, where it promotes glycogen clustering and supports cell survival . The protein contains specific domains that facilitate its interactions with both glycogen and components of the autophagy machinery, making it a key mediator in the cellular response to metabolic stress and glycogen management .

What is the molecular weight range for detecting STBD1 in different species?

When using STBD1 antibodies in Western blot applications, researchers should expect different molecular weight ranges depending on the species being studied:

The calculated molecular weight of human STBD1 is approximately 41 kDa, while the observed molecular weight in Western blot applications is typically around 38 kDa . These slight variations in molecular weight can be attributed to post-translational modifications and should be considered when analyzing Western blot results. It is important to verify the specificity of the antibody in your experimental system and to include appropriate positive controls to ensure accurate detection .

What cell lines have been validated for STBD1 antibody applications?

Based on available validation data, STBD1 antibodies have been successfully tested in the following cell lines and tissues:

What are the optimal antibody dilutions for different applications involving STBD1?

Proper antibody dilution is critical for achieving specific signal with minimal background. The following table provides recommended dilution ranges for STBD1 antibodies based on validation data:

It is strongly recommended to perform titration experiments to determine the optimal dilution for your specific experimental conditions. Factors such as expression level, sample type, and detection method can influence the optimal antibody concentration . When using a new antibody preparation or working with a new experimental system, it is advisable to test a range of dilutions to identify the concentration that provides the best signal-to-noise ratio.

What buffer conditions and antigen retrieval methods are recommended for STBD1 immunohistochemistry?

For optimal STBD1 detection in fixed tissue sections, the following antigen retrieval methods have been validated:

Primary recommendation: TE buffer (pH 9.0) for heat-induced epitope retrieval .
Alternative method: Citrate buffer (pH 6.0) may also be effective for certain tissue types .

The choice of antigen retrieval method can significantly impact antibody binding efficiency. The alkaline TE buffer (pH 9.0) appears to be particularly effective for STBD1 detection, likely due to the protein's structural properties and epitope accessibility after fixation. For challenging samples or when signal intensity is suboptimal, comparing both retrieval methods can help determine the most effective approach for your specific tissue type and fixation conditions .

How should STBD1 antibodies be stored to maintain their performance?

For optimal longevity and performance of STBD1 antibodies, follow these storage recommendations:

• Store at -20°C in the buffer provided (typically PBS with 0.02% sodium azide and 50% glycerol, pH 7.3)

• Antibodies are generally stable for one year after shipment when stored properly

• For small volume antibodies (e.g., 20 μl sizes), note that they may contain 0.1% BSA as a stabilizer

• Aliquoting is generally unnecessary for -20°C storage but may be advisable for frequently used antibodies to avoid freeze-thaw cycles

Multiple freeze-thaw cycles can degrade antibody performance over time. If the antibody will be used frequently, consider preparing small working aliquots for routine use while maintaining a master stock at -20°C .

How does STBD1 interact with the autophagy machinery to mediate glycophagy?

STBD1 functions as a bridge between glycogen particles and the autophagy machinery through specific protein-protein interactions. Key findings reveal that:

STBD1 contains functional Atg8-family interacting motifs (AIMs) that mediate its binding to GABARAPL1, a mammalian homolog of the yeast Atg8 protein . Through site-directed mutagenesis, researchers have identified that STBD1 contains two potential AIM regions with the critical residues being W203, V206, W212, and V215 . Mutation of these residues (particularly W203A and V206A) significantly disrupts the interaction between STBD1 and GABARAPL1, as demonstrated through co-immunoprecipitation experiments .

The interaction with GABARAPL1 is essential for recruiting glycogen particles to autophagosomes for subsequent degradation in lysosomes. This provides a molecular mechanism for how glycogen is selectively targeted for degradation via the autophagy-lysosomal pathway rather than the cytosolic pathway involving glycogen phosphorylase .

For researchers investigating this interaction, co-immunoprecipitation assays using anti-FLAG affinity gel with FLAG-tagged GABARAPL1 and HA-tagged STBD1 provide an effective approach to study these protein-protein interactions and the effects of specific mutations .

What role does STBD1 play in endoplasmic reticulum stress responses?

STBD1 has been identified as a key player in cellular responses to endoplasmic reticulum (ER) stress, with important implications for cell survival mechanisms:

Recent research has demonstrated that ER stress stimulates an increase in STBD1 protein levels in skeletal muscle precursor cells (myoblasts) . This upregulation of STBD1 is specifically required for the formation of glycogen clusters at the ER membrane during stress conditions .

The biological significance of this ER stress-induced response appears to support cell survival during periods of stress. The clustering of glycogen at the ER membrane may serve as an adaptive mechanism that helps cells maintain energy homeostasis during stress conditions .

For researchers investigating this phenomenon, immunofluorescence microscopy using antibodies against STBD1 (with appropriate controls) can effectively visualize the formation of these glycogen clusters. Techniques such as structured light acquisition via an Apotome can provide high-resolution images of STBD1 localization and glycogen clustering during ER stress conditions .

How do STBD1 mutations or dysregulation contribute to disease pathogenesis?

STBD1 dysfunction has been implicated in several pathological conditions through various mechanisms:

Pompe disease: As a glycogen storage disorder, Pompe disease involves abnormal accumulation of glycogen in lysosomes due to deficiency of acid α-glucosidase (GAA). STBD1-dependent glycophagy represents a potential therapeutic target in this condition, as modulating STBD1 function could potentially alter the trafficking of glycogen to lysosomes .

Cancer: Deletions and/or mutations in STBD1 have been associated with promoting tumorigenesis, suggesting a potential tumor suppressor role for this protein . The dysregulation of glycogen metabolism is increasingly recognized as an important factor in cancer cell metabolism and survival.

Parkinson's disease and cardiac diseases: STBD1 has also been implicated in these conditions, likely through mechanisms related to altered glycogen metabolism and cellular stress responses .

Research approaches to study STBD1 in disease contexts include immunohistochemical analysis of patient tissues (using validated STBD1 antibodies), genetic studies examining STBD1 mutations or expression levels in patient samples, and functional studies in relevant cell and animal models .

What considerations are important when designing co-localization studies involving STBD1?

For effective co-localization studies investigating STBD1's interactions with other cellular components:

• Antibody selection and validation: When performing double immunofluorescence staining, verify that the STBD1 antibody is compatible with the fixation and permeabilization conditions required for the other target protein's antibody. Consider using antibodies raised in different host species to avoid cross-reactivity in secondary antibody detection .

• Subcellular markers: Include appropriate markers for relevant subcellular compartments such as:

  • ER membrane markers (e.g., calnexin or PDI) to confirm STBD1's predominant localization

  • Autophagosome markers (e.g., LC3 or other ATG8 family members) to study glycophagy

  • Lysosomal markers (e.g., LAMP1) to track glycogen delivery to lysosomes

• Imaging parameters: For high-resolution visualization of STBD1 localization, structured light acquisition (using systems like the Zeiss Apotome) provides superior results compared to conventional widefield microscopy. A Plan Apochromat 63× oil immersion objective is recommended for optimal resolution .

• Controls and quantification: Include appropriate negative controls (isotype control antibodies) and positive controls (cell types known to express STBD1). Quantitative co-localization analysis using established methods (e.g., Pearson's correlation coefficient) is essential for rigorous assessment of spatial relationships .

What are common issues in STBD1 detection and how can they be resolved?

Researchers may encounter several challenges when working with STBD1 antibodies. Here are common problems and their solutions:

For challenging samples, particularly in immunohistochemistry applications, comparing different antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0) may help optimize signal detection .

How can researchers validate the specificity of STBD1 antibodies?

Rigorous validation of antibody specificity is essential for reliable STBD1 research. Recommended validation approaches include:

• Genetic approaches:

  • siRNA or shRNA knockdown of STBD1 should result in reduced or absent signal

  • Overexpression of tagged STBD1 should show co-localization with antibody staining

  • CRISPR/Cas9 knockout cells provide the most stringent control for antibody specificity

• Biochemical validation:

  • Western blot analysis should show a band of the expected molecular weight (35-43 kDa depending on species)

  • Immunoprecipitation followed by mass spectrometry can confirm antibody specificity

  • Pre-adsorption of the antibody with the immunizing peptide should abolish specific signals

• Cross-validation:

  • Compare results from multiple antibodies targeting different epitopes of STBD1

  • Correlate protein detection with mRNA expression data

  • Compare monoclonal (e.g., 67018-1-Ig) and polyclonal (e.g., 11842-1-AP) antibodies for consistent detection patterns

When publishing research using STBD1 antibodies, clearly document the validation methods employed to establish antibody specificity, as this enhances reproducibility and reliability of the findings.

How should researchers approach contradictory findings in STBD1 studies?

When faced with inconsistent or contradictory results in STBD1 research:

• Verify antibody specificity and experimental conditions:

  • Different antibody clones may recognize distinct epitopes with varying accessibility depending on experimental conditions

  • Confirm that the antibody recognizes the specific isoform or domain of STBD1 being studied

• Consider context-dependent regulation:

  • STBD1 expression and function can be significantly altered by cellular stress conditions, particularly ER stress

  • Differences in cell type, differentiation state, or metabolic conditions may affect STBD1 expression and subcellular localization

• Evaluate technical variables:

  • Fixation methods significantly impact epitope preservation and accessibility

  • Buffer conditions, detergents, and sample preparation methods can affect protein extraction and antibody binding

  • When comparing studies, consider differences in methodology that might explain conflicting results

• Integrate multiple approaches:

  • Combine antibody-based detection with orthogonal methods such as mRNA analysis, mass spectrometry, or functional assays

  • Use multiple antibodies targeting different epitopes to build a more complete understanding of STBD1 biology

For particularly challenging questions, consider collaborative approaches with laboratories using complementary techniques to provide a more comprehensive analysis of STBD1 function in your specific research context.

What emerging technologies show promise for advancing STBD1 research?

Several cutting-edge approaches offer new opportunities for investigating STBD1 biology:

• Advanced imaging techniques:

  • Super-resolution microscopy (STORM, PALM, or STED) can provide nanoscale visualization of STBD1 interactions with glycogen and autophagy machinery

  • Live-cell imaging using fluorescently tagged STBD1 can reveal dynamic aspects of glycophagy and glycogen clustering during cellular stress responses

• Proximity labeling approaches:

  • BioID or APEX2 proximity labeling fused to STBD1 can identify novel protein interactions in the glycophagy pathway

  • These techniques are particularly valuable for identifying transient or weak interactions that may be missed by traditional co-immunoprecipitation approaches

• Real-time diagnostic tools:

  • Development of biosensors to monitor STBD1-mediated glycophagy in real-time

  • These approaches could provide critical insights into the dynamics and regulation of glycogen trafficking to lysosomes

• Systems biology integration:

  • Multi-omics approaches combining proteomics, transcriptomics, and metabolomics can provide a comprehensive view of how STBD1 functions within broader cellular networks

  • Computational modeling of glycogen metabolism incorporating STBD1-dependent processes can generate new hypotheses about its regulation and function

The development and application of these advanced technologies will be essential for addressing the complexity of STBD1 biology and its roles in health and disease.

What therapeutic opportunities exist in targeting STBD1 for glycogen-related diseases?

STBD1 represents a promising therapeutic target for several glycogen-related disorders:

• Pompe disease and other glycogen storage disorders:

  • Modulating STBD1 function could potentially alter glycogen trafficking to lysosomes, providing a complementary approach to enzyme replacement therapy

  • Both enhancement and inhibition of STBD1-mediated glycophagy might be therapeutically beneficial depending on the specific disease context

• Cancer metabolism:

  • Given the links between STBD1 dysregulation and tumorigenesis, targeting glycophagy could represent a novel approach to cancer therapy

  • STBD1 could serve as a biomarker for specific cancer subtypes with altered glycogen metabolism

• Neurodegenerative conditions:

  • The involvement of STBD1 in Parkinson's disease suggests potential applications in neurodegenerative conditions

  • Modulating glycophagy could potentially influence protein aggregation or neuronal energy metabolism

• Therapeutic strategies:

  • Small molecule modulators of STBD1-glycogen or STBD1-GABARAPL1 interactions

  • Gene therapy approaches to correct STBD1 mutations or modulate its expression

  • Cell-based therapies incorporating engineered STBD1 function

Further research is needed to elucidate the precise mechanisms by which STBD1 contributes to disease pathogenesis and to develop targeted therapeutic interventions that specifically modulate its function in relevant tissues.